Merck/Schering: The Next Wave Of Consolidation
This article was originally published in The Pink Sheet Daily
Executive Summary
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
You may also be interested in...
Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits
Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.
Merck Folds In Schering-Plough, Begins Job Cuts
Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.
Merck Folds In Schering-Plough, Begins Job Cuts
Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.